Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 1/20 | 0.39 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.36 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.35 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14378917 | 1.00 | ADK (0.39) | ADKSLC29A1PRMT5WDR77ADORA3 | |
| SCHEMBL1737262 | 0.91 | XDH (0.39) | ADKSLC29A1PRMT5WDR77 | |
| SCHEMBL12963413 | 0.84 | ADK (0.33) | ADKPRMT5WDR77ADORA3METTL3 | |
| SCHEMBL13020654 | 0.84 | ADK (0.33) | ADKPRMT5WDR77ADORA3METTL3 | |
| SCHEMBL14154376 | 0.84 | ADK (0.43) | ADKSLC29A1PRMT5WDR77ADORA3 | |
| SCHEMBL14378921 | 0.82 | — | — | |
| SCHEMBL13104990 | 0.82 | ADK (0.30) | ADK | |
| SCHEMBL14378918 | 0.82 | ADK (0.30) | ADK | |
| SCHEMBL14378919 | 0.81 | GK (0.34) | — | |
| SCHEMBL14154334 | 0.80 | ADK (0.44) | ADKSLC29A1PRMT5WDR77ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331397-A1 | 2-5A ANALOGS AND THEIR METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-7807653-B2 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-10-05 | — | — | US | disclosed |
| US-7598230-B2 | For the treatment of viral infections, microbial infections, and proliferative disorders; contain di- or triphosphate moeity mimetics, such as those containing boron anions | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2009-10-06 | — | — | US | disclosed |
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-15 | — | — | US | disclosed |
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-08 | — | — | US | disclosed |
| US-7285658-B2 | Nucleotide mimics and their prodrugs | BIOTA, INC. (US) | 2007-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | ADK 102/4885SLC29A1 19/4885PRMT5 2032/4885 |
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | ADK 102/4885SLC29A1 19/4885PRMT5 2032/4885 |
| US-20100331397-A1 | 2-5A ANALOGS AND THEIR METHODS OF USE | RNASEL, RNASE1, RNASEH1 | ADK 932/4885SLC29A1 1409/4885PRMT5 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.